Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75]

•PD-L1 status should be considered a new a new predictive biomarker in advanced NSCLC.•Upfront Immunotherapy is standard treatment in a subgroup of NSCLC patients.•Efficacy of these treatments according to the range of different PD-L1 expression remains unclear.